Journal
LEUKEMIA & LYMPHOMA
Volume 53, Issue 11, Pages 2105-2115Publisher
INFORMA HEALTHCARE
DOI: 10.3109/10428194.2012.692088
Keywords
Fludarabine; rituximab; fluorescence in situ hybridization; 17p deletion
Categories
Ask authors/readers for more resources
Aberrations of the TP53 pathway, whether by deletion or mutation, are increasingly recognized as one of the most important biological risk factors in chronic lymphocytic leukemia. Yet, there is little consensus on how to assess for TP53 defects in the clinic, and very few clinical studies to guide optimal management of such patients. In this review, we discuss the state-of-the-art in the assessment of the TP53 pathway, and review the evidence-base for therapeutic recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available